natgillin/translations-raw huggingface dataset:
Docetaxel Teva 80 mg/2,88 ml koncentrat til infusionsvæske, opløsning, er en klar viskøs, gul til gulbrun opløsning, som indeholder 27,73 mg/ml docetaxel (vandfri) i polysorbat 80.
Docetaxel Teva 80 mg/2.88 ml concentrate for solution for infusion is a clear viscous, yellow to brown-yellow solution containing 27.73 mg/ml docetaxel (anhydrous) in polysorbate 80.
Docetaxel Teva anvendes sammen med cisplatin og 5-fluorouracil (andre lægemidler mod kræft). kræft i hoved- og halsregionen hos patienter, hvis kræft er lokalt fremskreden (som er vokset, men ikke har spredt sig).
Docetaxel Teva is used with cisplatin and 5-fluorouracil (other anticancer medicines); head and neck cancer in patients whose cancer is locally advanced (a cancer that has grown but has not spread).
Docetaxel Teva blev administreret som infusion over 1 time, alle andre lægemidler blev givet intravenøst på dag 1 hver 3. uge.
Docetaxel was administered as a 1-hour infusion, all other medicinal products were given as intraveinously on day 1 every three weeks.
Docetaxel Teva er et antineoplastisk stof, og ligesom andre potentielle toksiske stoffer skal det behandles med forsigtighed ved håndtering og tilberedning af Docetaxel Teva-opløsningerne.
Docetaxel Teva is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing Docetaxel solutions.
Docetaxel Teva er et antineoplastisk stof, og som med andre potentielle toksiske lægemidler, skal man udvise forsigtighed ved brug og fremstilling af Docetaxel Teva-opløsninger.
Docetaxel Teva is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing Docetaxel Teva solutions.
Docetaxel Teva er et ‘generisk lægemiddel’.
Docetaxel Teva is a ‘generic medicine’.
Docetaxel Teva er indiceret til behandling af patienter med lokalt fremskreden eller metastatisk ikke- småcellet lungekræft efter behandlingssvigt af kemoterapi.
Docetaxel Teva is indicated for the treatment of patients with locally advanced or metastatic non- small cell lung cancer after failure of prior chemotherapy.
Docetaxel Teva er ordineret af din læge til behandling af brystkræft, specielle former for lungekræft (ikke-småcellet lungekræft), prostatakræft, gastrisk kræft eller hoved- og halskræft:
Docetaxel Teva has been prescribed by your doctor for the treatment of breast cancer, special forms of lung cancer (non-small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer:
Docetaxel Teva i kombination med trastuzumab er indiceret til behandling af patienter med metastatisk brystkræft, som har HER2-positive tumorer, og som ikke tidligere har modtaget kemoterapi mod metastatisk sygdom.
Docetaxel Teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.
Docetaxel Teva infusionsopløsning skal bruges inden for 4 timer og anvendes under aseptiske forhold som en 1-times infusion ved stuetemperatur (under 25 °C) og under normale lysforhold.
The Docetaxel Teva infusion solution should be used within 4 hours and should be aseptically administered as a 1-hour infusion under room temperature (below 25°C) and normal lighting conditions.
Docetaxel Teva Pharma 20 mg koncentrat og solvens til infusionsvæske, opløsning.
Docetaxel Teva Pharma 20 mg concentrate and solvent for solution for infusion
Docetaxel Teva Pharma 20 mg koncentrat til infusionsvæske, opløsning docetaxel
Docetaxel Teva Pharma 20 mg concentrate for solution for infusion docetaxel
Docetaxel Teva Pharma 80 mg hætteglas
Docetaxel Teva Pharma 80 mg vial
Docetaxel Teva Pharma 80 mg koncentrat og solvens til infusionsvæske, opløsning.
Docetaxel Teva Pharma 80 mg concentrate and solvent for solution for infusion
Docetaxel Teva Pharma 80 mg, koncentrat til infusionsvæske, opløsning docetaxel
Docetaxel Teva Pharma 80 mg concentrate for solution for infusion docetaxel
Docetaxel Teva Pharma er et antineoplastisk stof, og ligesom andre potentielle toksiske stoffer skal det behandles med forsigtighed ved håndtering og tilberedning af Docetaxel Teva Pharma- opløsningerne.
Docetaxel Teva Pharma is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing Docetaxel solutions.
Docetaxel Teva Pharma er et ‘generisk lægemiddel’.
Docetaxel Teva Pharma is a ‘generic medicine’.
Docetaxel Teva Pharma er ordineret af din læge til behandling af fremskreden brystkræft, specielle former for lungekræft (ikke-småcellet lungekræft) og prostatakræft:
Docetaxel Teva Pharma has been prescribed by your doctor for the treatment of advanced breast cancer, special forms of lung cancer (non-small cell lung cancer) and prostate cancer:
Docetaxel Teva Pharma koncentrat til infusionsvæske, opløsning, er en klar viskøs, gul til gulbrun opløsning.
Docetaxel Teva Pharma concentrate for solution for infusion is a clear viscous, yellow to brown- yellow solution.
Docetaxel Teva Pharma må IKKE anvendes, hvis du er gravid, medmindre det klart er anvist af din læge.
Docetaxel Teva Pharma must NOT be administered if you are pregnant unless clearly indicated by your doctor.
Docetaxel Teva Pharma-infusionsopløsning skal bruges inden for 4 timer og anvendes under aseptiske forhold som en 1-times infusion ved stuetemperatur (under 25°C) og under normale lysforhold.
The Docetaxel Teva Pharma infusion solution should be used within 4 hours and should be aseptically administered as a 1-hour infusion under room temperature (below 25°C) and normal lighting conditions.
Docetaxel Teva-infusionsopløsning skal bruges inden for 4 timer og anvendes under aseptiske forhold som en 1-times infusion ved stuetemperatur (under 25 °C) og under normale lysforhold.
The Docetaxel Teva infusion solution should be used within 4 hours and should be aseptically administered as a 1-hour infusion under room temperature (below 25°C) and normal lighting conditions.
Docetaxel Winthrop 160 mg/8 ml koncentrat til infusionsvæske, opløsning docetaxel
Docetaxel Winthrop 160 mg/8 ml concentrate for solution for infusion docetaxel
Docetaxel Winthrop 160 mg/8 ml koncentrat til infusionsvæske, opløsning kræver INGEN forudgående fortynding med en solvens, men er klar til tilsætning til infusionsvæske.
Docetaxel Winthrop 160 mg/8 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Docetaxel Winthrop 160 mg/8 ml koncentrat til infusionsvæske, opløsning.
Docetaxel Winthrop 160 mg/8 ml concentrate for solution for infusion.
Docetaxel Winthrop 20 mg/1 ml koncentrat til infusionsvæske, opløsning docetaxel
Docetaxel Winthrop 20 mg/1 ml concentrate for solution for infusion docetaxel
Docetaxel Winthrop 20 mg/1 ml koncentrat til infusionsvæske, opløsning kræver INGEN forudgående fortynding med en solvens, men er klar til tilsætning til infusionsvæske.
Docetaxel Winthrop 20 mg/1 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Docetaxel Winthrop 20 mg/1 ml koncentrat til infusionsvæske, opløsning.
Docetaxel Winthrop 20 mg/1 ml concentrate for solution for infusion
Docetaxel Winthrop 20 mg/1 ml sterilt koncentrat docetaxel
Docetaxel Winthrop 20 mg/1 ml sterile concentrate docetaxel
Docetaxel Winthrop 80 mg/4 ml koncentrat til infusionsvæske, opløsning docetaxel
Docetaxel Winthrop 80 mg/4 ml concentrate for solution for infusion docetaxel
Docetaxel Winthrop 80 mg/4 ml koncentrat til infusionsvæske, opløsning kræver INGEN forudgående fortynding med en solvens, men er klar til tilsætning til infusionsvæske.
Docetaxel Winthrop 80 mg/4 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Docetaxel Winthrop 80 mg/4 ml koncentrat til infusionsvæske, opløsning.
Docetaxel Winthrop 80 mg/4 ml concentrate for solution for infusion
Docetaxel Winthrop anvendes sammen med cisplatin og 5-fluorouracil (andre lægemidler mod kræft), kræft i hoved- og halsregionen hos patienter, hvis kræft er fremskreden (er begyndt at sprede sig).
Docetaxel Winthrop is used with cisplatin and 5-fluorouracil (other anticancer medicines); head and neck cancer in patients whose cancer is locally advanced (a cancer that has grown but has not spread).
Docetaxel Winthrop anvendes sammen med cisplatin og 5-fluorouracil.
Docetaxel Winthrop is used with cisplatin and 5-fluorouracil.
Docetaxel Winthrop anvendes til behandling af følgende kræftformer:
Docetaxel Winthrop is used to treat the following types of cancer:
Docetaxel Winthrop blev administreret som infusion over 1 time, alle andre lægemidler blev givet intravenøst på dag 1 hver 3. uge.
Docetaxel Winthrop was administered as a 1-hour infusion, all other medicinal products were given intraveinously on day 1 every three weeks.
Docetaxel Winthrop bør kun anvendes på afdelinger, der er specialiseret i kemoterapi, under overvågning af en læge, der er specialiseret i brug af kemoterapi.
Docetaxel Winthrop should be used in wards specialising in chemotherapy (using medicines to treat cancer) under the supervision of a doctor who is qualified in the use of chemotherapy.
Docetaxel Winthrop er et antineoplastisk stof, og ligesom andre potentielle toksiske stoffer skal det behandles med forsigtighed ved håndtering og tilberedning af Docetaxel Winthrop-opløsningerne.
Docetaxel Winthrop is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing Docetaxel Winthrop solutions.
Docetaxel Winthrop er et lægemiddel, der indeholder det aktive stof docetaxel.
Docetaxel Winthrop is a medicine that contains the active substance docetaxel.
Docetaxel Winthrop er indiceret til behandling af patienter med lokalt fremskreden eller metastatisk ikke-småcellet lungekræft efter behandlingssvigt af kemoterapi.
Docetaxel Winthrop is indicated for the treatment of patients with locally advanced or metastatic non- small cell lung cancer after failure of prior chemotherapy.
Docetaxel Winthrop er indiceret til behandling af patienter med lokalt fremskreden eller metastatisk ikke-småcellet lungekræft efter behandlingssvigt af kemoterapi.
Docetaxel Winthrop is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.
Docetaxel Winthrop er ordineret af din læge til behandling af bryst- eller specielle former for lungekræft (ikke-småcellet lungekræft), prostata kræft, gastrisk kræft eller hoved- og hals-kræft:
Docetaxel Winthrop has been prescribed by your doctor for the treatment of breast cancer, special forms of lung cancer (non-small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer:
Docetaxel Winthrop gives hver tredje uge ved en infusion, der varer en time.
Docetaxel Winthrop is given as a one-hour infusion every three weeks.
Docetaxel Winthrop gives som infusion i en blodåre (intravenøs anvendelse).
Docetaxel Winthrop will be given by infusion into one of your veins (intravenous use).
Docetaxel Winthrop i kombination med capecitabin
Docetaxel Winthrop in combination with capecitabine
Docetaxel Winthrop i kombination med capecitabin er indiceret til behandling af patienter med lokal fremskreden eller metastatisk brystkræft efter svigt af cytotoksisk kemoterapi.
Docetaxel Winthrop in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.
Docetaxel Winthrop i kombination med cisplatin er indiceret til behandling af patienter med inoperabel lokalt fremskreden eller metastatisk ikke-småcellet lungekræft hos patienter, der ikke tidligere har fået kemoterapi mod denne tilstand.
Docetaxel Winthrop in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.
Docetaxel Winthrop i kombination med cisplatin og 5-fluoruracil er indiceret til behandling af patienter med metastatisk gastrisk adenokarcinom, inklusive adenokarcinom i den gastrooesophageale forbindelse, som ikke tidligere har fået kemoterapi mod metastatisk sygdom.
Docetaxel Winthrop in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.
Docetaxel Winthrop i kombination med cisplatin og 5-fluoruracil er indiceret til indledende behandling af patienter med inoperable, lokale, fremskredne skællede celle-carcinoma i hoved og hals.
Docetaxel Winthrop in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
Docetaxel Winthrop i kombination med doxorubicin
Docetaxel Winthrop in combination with doxorubicin
Docetaxel Winthrop i kombination med doxorubicin er indiceret til behandling af patienter med lokalt fremskreden eller metastatisk brystkræft, som ikke tidligere har fået kemoterapi mod denne tilstand.
Docetaxel Winthrop in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.
Docetaxel Winthrop i kombination med doxorubicin og cyclophosphamid er indiceret til adjuverende behandling af patienter med:
Docetaxel Winthrop in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:
Docetaxel Winthrop i kombination med doxorubicin og cyclophosphamid: Adjuverende behandling
Docetaxel Winthrop in combination with doxorubicin and cyclophosphamide: adjuvant therapy
Docetaxel Winthrop i kombination med platinmidler hos patienter der ikke tidligere er behandlet med kemoterapi
Docetaxel Winthrop in combination with platinum agents in chemotherapy-naïve patients
Docetaxel Winthrop i kombination med prednison eller prednisolon er indiceret til behandling af patienter med hormonrefraktær metastatisk prostatakræft.
Docetaxel Winthrop in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.
Docetaxel Winthrop i kombination med trastuzumab
Docetaxel Winthrop in combination with trastuzumab
Docetaxel Winthrop i kombination med trastuzumab er indiceret til behandling af patienter med metastatisk brystkræft, hvis tumorer overudtrykker HER2, og som ikke tidligere har fået kemoterapi mod metastatisk sygdom.
Docetaxel Winthrop in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.
Docetaxel Winthrop indeholder alkohol.
Docetaxel Winthrop contains alcohol.
Docetaxel Winthrop indeholder ethanol (alkohol)
Docetaxel Winthrop contains ethanol (alcohol)
Docetaxel Winthrop kan bruges som eneste behandling, når andre lægemidler har været uden virkning.
Docetaxel Winthrop can be used on its own after other treatments have failed.
Docetaxel Winthrop koncentrat til infusionsvæske, opløsning er en lys gul til brunliggul opløsning.
Docetaxel Winthrop concentrate for solution for infusion is a pale yellow to brownish-yellow solution.
Docetaxel Winthrop monoterapi er indiceret til behandling af patienter med lokalt fremskreden eller metastatisk brystkræft efter behandlingssvigt af kemoterapi.
Docetaxel Winthrop monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy.
Docetaxel Winthrop må ikke anvendes til patienter med netrofiltal under 1 500 celler/mm3 eller til patienter med alvorlige leverproblemer.
Docetaxel Winthrop must not be used in patients who have a neutrophil count of less than 1,500 cells/mm3 or who have severe problems with their liver.
Docetaxel Winthrop må ikke anvendes til personer, som er overfølsomme (allergiske) over for docetaxel eller nogen af indholdsstofferne.
Docetaxel Winthrop must not be used in people who are hypersensitive (allergic) to docetaxel or any of the other ingredients.
Docetaxel Winthrop må IKKE anvendes, hvis du er gravid eller planlægger at blive gravid, medmindre din læge udtrykkelig ønsker det.
Docetaxel Winthrop must NOT be administered if you are pregnant unless clearly indicated by your doctor.
Docetaxel Winthrop må kun bruges, når neutrofiltallet (koncentrationen af en form for hvide blodlegemer) er normalt (mindst 1 500 celler/mm3).
Docetaxel Winthrop is only used when the neutrophil count (the level of a type of white blood cell in the blood) is normal (at least 1,500 cells/mm3).
Docetaxel Winthrop som enkeltstof
Docetaxel Winthrop as single agent
Docetaxel Winthrop vil blive administreret af personale med en sundhedsfaglig uddannelse.
Docetaxel Winthrop will be administered to you by a healthcare professional.
Docetaxel Winthrops sikkerhed og virkning ved nasofaryngealt karcinom hos børn i alderen 1 måned til under 18 år er endnu ikke klarlagt.
The safety and efficacy of Docetaxel Winthrop in nasopharyngeal carcinoma in children aged 1 month to less than 18 years have not yet been established.
Docetaxel øgede responsraten (33 % vs.
Docetaxel increased response rate (33% vs.
Docetaxel+ Cis+5-FU n = 177
Docetaxel + Cis + 5-FU n = 177
Docetaxel+ Cis+5-FU n = 177
Docetaxel+Cis+5-FU n=177
Docetaxel-dosis bør reduceres fra 75 til 60 mg/m2, hvis der trods anvendelse af G-CSF opstår: 1) febril neutropeni, 2) prolongeret neutropeni eller 3) neutropenisk infektion.
If an episode of febrile neutropenia, prolonged neutropenia or neutropenic infection occurs despite G-CSF use, the docetaxel dose should be reduced from 75 to 60 mg/m2.
Docetaxel-dosis bør reduceres fra 75 til 60 mg/m2, hvis der trods anvendelse af G-CSF opstår: 1) febril neutropeni, 2) prolongeret neutropeni, 3) eller neutropenisk infektion.
If an episode of febrile neutropenia, prolonged neutropenia or neutropenic infection occurs despite G-CSF use, the docetaxel dose should be reduced from 75 to 60 mg/m2.
Docetaxel-dosis bør reduceres fra 75 til 60 mg/m², hvis der trods anvendelse af G¬CSF opstår: 1) febril neutropeni, 2) prolongeret neutropeni, 3) eller neutropenisk infektion.
If an episode of febrile neutropenia, prolonged neutropenia or neutropenic infection occurs despite G-CSF use, the docetaxel dose should be reduced from 75 to 60 mg/m².
Docetaxel-infusionsvæsken er overmættet, den kan derfor udkrystallisere over tid.
Docetaxel infusion solution is supersaturated and may therefore crystallize over time.
Docetaxel-infusionsvæsken er overmættet, den kan derfor udkrystallisere over tid.
Docetaxel infusion solution is supersaturated, therefore may crystallize over time.
Docetaxel-infusionsvæsken skal bruges inden for 4 timer og anvendes under aseptiske forhold som en
The docetaxel infusion solution should be used within 4 hours and should be aseptically administered as a 1 hour infusion under room temperature and normal lighting conditions.
Docetaxel1 n = 94
Docetaxel1 n=94
Docetaxels farmakokinetik under tilstedeværelse af prednison blev undersøgt hos patienter med metastatisk prostatakræft.
Docetaxel pharmacokinetics in the presence of prednisone was studied in patients with mestatic prostate cancer.
Docetaxels kinetiske profil er dosis-uafhængig og i overensstemmelse med en 3- compartment farmakokinetisk model, med halveringstider for α, β og γ faserne på henholdsvis 4 min., 36 min. og 11,1 time.
The kinetic profile of docetaxel is dose independent and consistent with a three-compartment pharmacokinetic model with half lives for the α, β and γ phases of 4 min, 36 min and 11.1 h, respectively.
Docetaxels kinetiske profil er dosis-uafhængig og i overensstemmelse med en 3- compartment farmakokinetisk model, med halveringstider for α-, β- og γ-faserne på henholdsvis 4 min., 36 min. og 11,1 time.
The kinetic profile of docetaxel is dose independent and consistent with a three-compartment pharmacokinetic model with half lives for the α, β and γ phases of 4 min, 36 min and 11.1 h, respectively.
Docetaxels kinetiske profil er dosis-uafhængig og i overensstemmelse med en 3- compartment farmakokinetisk model, med halveringstider for ,  og  faserne på henholdsvis 4 min., 36 min. og 11,1 time.
The kinetic profile of docetaxel is dose independent and consistent with a three-compartment pharmacokinetic model with half lives for the ,  and  phases of 4 min, 36 min and 11.1 h, respectively.
Docetaxels kinetiske profil er dosis-uafhængig og i overensstemmelse med en 3- kompartment farmakokinetisk model, med halveringstider for α-, β- og γ-faserne på henholdsvis 4 min., 36 min. og 11,1 time.
The kinetic profile of docetaxel is dose independent and consistent with a three-compartment pharmacokinetic model with half lives for the α, β and γ phases of 4 min, 36 min and 11.1 h, respectively.
Docetaxels kinetiske profil er dosisuafhængig og i overensstemmelse med en
20-115 mg/m² in phase I studies.
Docetaxels sikkerhed og effekt i induktionsbehandlingen af patienter med lokalt fremskreden pladecellecarcinom i hoved og hals (SCCHN) blev evalueret i et åbent, randomiseret fase III- multicenterstudie (TAX 324).
The safety and efficacy of docetaxel in the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) was evaluated in a randomized, multicenter open-label, phase III study (TAX324).
Docetaxels sikkerhed og effekt i induktionsbehandlingen af patienter med pladecellecarcinom i hoved og hals (SCCHN) blev evalueret i et åbent, randomiseret fase III-multicenterstudie (TAX 323).
The safety and efficacy of docetaxel in the induction treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) was evaluated in a phase III, multicenter, open-label, randomized study (TAX323).
Docetaxels sikkerhed og virkning af Docetaxel Teva Pharma ved nasofaryngealt karcinom hos børn i alderen 1 måned til under 18 år er endnu ikke klarlagt.
The safety and efficacy of Docetaxel Teva Pharma in nasopharyngeal carcinoma in children aged 1 month to less than 18 years have not yet been established.
Dofetilid  (Ikke undersøgt, potentiel stigning via hæmning af OCT2-transporter).
Dofetilide  (Not studied, potential increase via inhibition of OCT2 transporter)
Dofetilid  (Ikke undersøgt, potentielt stigning via hæmning af
Dofetilide  (Not studied, potential increase via inhibition of OCT2 transporter)
Dog anbefales regelmæssig monitorering af renalfunktion og serumkalium hos hunde med renal svækkelse, da der kan være en øget risiko for hyperkaliæmi
However, in dogs with renal impairment regular monitoring of renal function and serum potassium levels is recommended as there may be an increased risk of hyperkalaemia.
Dog blev der set en bedre effekt hos Parkinsons patienter med moderat demens.
However a greater treatment effect was seen in Parkinson’s disease patients with moderate dementia.
Dog blev der set en bedre effekt hos Parkinsons patienter med moderat demens.
However, a greater treatment effect was seen in Parkinson’s disease patients with moderate dementia.
Dog blev følgende bivirkninger set hyppigere: infektion i næse og hals, hovedpine, kvalme samt nedsat antal hvide blodlegemer.
Some side effects were seen more often: inflamed nose and throat, headache, feeling sick (nausea) and lower white blood cell counts. .
Dog blev grad 3 overfølsomhedsreaktioner associeret med målbare anti-terapeutiske antistoffer set hos 2 ud af 366 Perjeta-behandlede patienter (0,5%) i fase I- og fase II-studier.
However, Grade 3 hypersensitivity reactions associated with detectable ATAs occurred in 2 of 366 Perjeta-treated patients (0.5%) in phase I and II studies.
Dog bør den dosis, der gives en enkelt dag, ikke overskride 24 mg buprenorphin.
However, the dose given on any one day should not exceed 24 mg buprenorphine.